bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A (NASDAQ:BLUE) | Seeking Alpha
MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
3 Top Biotech Buyout Candidates in 2021 | The Motley Fool
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
Bluebird bio snares gene-editing tech in $156M buyout deal | Fierce Biotech
Bristol-Myers' Acquisition of - GuruFocus.com
Bluebird Spinoff 2seventy Bio Gets Its Own Wings :: Scrip
10 Takeover Targets of 2018
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first | Fierce Pharma
BLUEBIRDBIO
bluebird bio: Hold, Wait To See If Revenue Ramps (NASDAQ:BLUE) | Seeking Alpha
bluebird bio: One Of My Top Picks For 2021 (NASDAQ:BLUE) | Seeking Alpha
Bluebird Bio hits pause on rollout for ill-fated gene therapy Zynteglo as trial flags 2 cancer cases | Fierce Pharma
Mergers & Acquisitions - bluebird bio
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
5 Biotechs Drawing Buyout Buzz in 2018 | BioSpace
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert – GeekWire
Opinion: Three tech, three biotech companies that are top takeover targets in 2019 - MarketWatch
Bluebird Bio (BLUE) Stock Price, News & Info | The Motley Fool
National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership | Fierce Pharma
